VRX Stock Forecast: Valeant Veers Away From Scandals, Rebrands Company

June 15, 2018
  This article was written by Julia Masch, a Financial Analyst at I Know First.




  Summary:

  • Q1 Highlights + Product Pipeline
  • Scandals + Valeant's Valiant Name Change
  • Current I Know First Forecast For VRX
premiumRead The Full Premium Article Subscribe to receive exclusive PREMIUM content here
52 Week High Stocks Biotech Stocks Forecast Pharma Stocks Forecast Premium Articles

Stock Price Valeant: Step by Step, Out of the Pit

July 25, 2017




This article was written by Mingyue Liu, a Financial Analyst at I Know First.

Valeant Pharmaceuticals International: Step by Step, Out of the Pit

"Medicine really matured me as a person because, as a physician, you're obviously dealing with life and death issues, issues much more serious than what we're talking about in entertainment. You can't get more serious than life and death. And if you can handle that, you can handle anything." (Ken Jeong)

Summary:
  • Debt divestiture through debt redemption and non-core business sales
  • Organic growth bolstered by potential launch of new drugs
  • Other tailwinds that may weigh on the company's growth

IBM priceRead The Full Premium Article

Subscribe to receive exclusive PREMIUM content here
Premium Articles

VRX Shares Quick Win by the Algorithm: A Valiant Effort to Recover

July 2, 2017

Quick Win by the Algorithm

Read The Full Forecast

Quick Win
Pharma Stocks Forecast

I Know First Reviews: September 8th 2016

September 8, 2016

I Know First Reviews

The stocks selected here in i know first reviews are the top performing stocks from I Know First: Barzil Package forecast for the last 3 month found under the article titled Bullish Stocks to Buy Based on Machine Learning: 63.61% Average Return in 3 Months.

Read The Full Forecast

I Know First Reviews
Algorithmic Performance I Know First Review

Valeant Pharmaceuticals Stock Prediction: The Road to Recovery

August 30, 2016
Samantha Fischler is a Financial Analyst at I Know First. She is currently a candidate for her bachelor’s degree in Accounting with a Concentration in Finance at Binghamton University.

  • Valeant Pharmaceuticals makes major changes to its leadership
  • Since October 2015, Valeant has been under investigation due to its connection to Philidor
  • Valeant is currently being sued by T. Rowe Price Group who allege that Valeant engaged in fraudulent activities that cost investor billions of dollars
  • The company reported losses in Q2 2016
  • Valeant is relaunching temporarily discontinued drugs and releasing new drugs
  • I Know First is currently bullish on VRX

premiumRead The Full Premium Article

Subscribe to receive exclusive PREMIUM content Here
Algorithmic Articles Premium Articles